Helius Medical Technologies calls the out-of-network reimbursement the first step in making the PoNS device more accessible to MS patients.

Helius Medical Technologies (NASDAQ:HSDT) shares are trading higher Wednesday after the company announced an authorized claim ...

Helius Medical Technologies, Inc. has announced that Aetna Healthcare has authorized payment for the PoNS Device at an out-of-network negotiated price of $18,350, making Aetna the third major ...

Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network ...

This figure reflects the typical adjusted price for out-of-network claims and represents an important validation of both the clinical need and the overall value of the PoNS Device. A Breakthrough ...

The PoNS device is a non-implantable, orally applied therapy that delivers neurostimulation through a mouthpiece to improve balance and gait. It is FDA-authorized as a short-term treatment for ...

Helius Medical Technologies will present significant new study results at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting, showcasing the sustained efficacy of its PoNS® device.

A new wave of innovation is reshaping small-cap markets across sectors including oncology, functional energy beverages, ...

CMSC attendees were encouraged at Helius’ recent successes in obtaining initial reimbursement from federal and private payers and appreciated the Company’s relentless effort to engage with health ...

Depending on the individual’s deductible and out-of-pocket costs, this claim may not result in an immediate PoNS Device sale. About the PoNS Device and PoNS Therapy The Portable Neuromodulation ...